TCI Wealth Advisors’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-2
Closed -$6 2498
2023
Q1
$6 Hold
2
﹤0.01% 2509
2022
Q4
$8 Hold
2
﹤0.01% 2478
2022
Q3
$0 Hold
2
﹤0.01% 2708
2022
Q2
$0 Hold
2
﹤0.01% 2621
2022
Q1
$0 Hold
2
﹤0.01% 2567
2021
Q4
$0 Hold
2
﹤0.01% 2608
2021
Q3
$0 Hold
2
﹤0.01% 2657
2021
Q2
$0 Hold
2
﹤0.01% 2522
2021
Q1
$0 Hold
2
﹤0.01% 2274
2020
Q4
$0 Hold
2
﹤0.01% 1713
2020
Q3
$0 Hold
2
﹤0.01% 1703
2020
Q2
$0 Hold
2
﹤0.01% 1724
2020
Q1
$0 Hold
2
﹤0.01% 1831
2019
Q4
$0 Hold
2
﹤0.01% 1722
2019
Q3
$0 Hold
2
﹤0.01% 1678
2019
Q2
$1K Hold
2
﹤0.01% 1362
2019
Q1
$1K Hold
2
﹤0.01% 1353
2018
Q4
$1K Hold
2
﹤0.01% 1363
2018
Q3
$2K Hold
2
﹤0.01% 1109
2018
Q2
$1K Hold
2
﹤0.01% 1429
2018
Q1
$1K Hold
2
﹤0.01% 1272
2017
Q4
$1K Hold
2
﹤0.01% 1308
2017
Q3
$1K Hold
2
﹤0.01% 1239
2017
Q2
$1K Hold
2
﹤0.01% 1261
2017
Q1
$3K Hold
2
﹤0.01% 877
2016
Q4
$1K Sell
2
-1
-33% -$399 ﹤0.01% 1273
2016
Q3
$1K Buy
3
+2
+200% +$894 ﹤0.01% 1261
2016
Q2
$0 Hold
1
﹤0.01% 1409
2016
Q1
$0 Hold
1
﹤0.01% 1433
2015
Q4
$0 Hold
1
﹤0.01% 1101
2015
Q3
$1K Hold
1
﹤0.01% 935
2015
Q2
$1K Buy
+1
New +$2.55K ﹤0.01% 924

TCI Wealth Advisors's HTGM Position: Q2 2023 in Review

TCI Wealth Advisors sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2023, closing a stake of 2 shares — an estimated $6 sold.

TCI Wealth Advisors first reported a position in HTGM in Q2 2015 and held it in 32 quarters. The position peaked at $3K in Q1 2017. 0 funds tracked by Wall St. Rank hold HTGM as of Q2 2023.

  • TCI Wealth Advisors reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 2 HTG Molecular Diagnostics, Inc. Common Stock shares in Q2 2023, an estimated $6.
  • TCI Wealth Advisors first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2015 and held it in 32 quarters.
  • TCI Wealth Advisors's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $3K in Q1 2017.
  • 0 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.